Clinical trials: Cardiac Allograft Vasculopathy
Heart Transplant, Acute Graft Rejection
Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
The investigators will use cardiac MRI to measure the myocardial perfusion reserve and amount of myocardial edema and fibrosis in heart-transplant patients with nonspecific allograft dysfunction in contrast to those with normal…
- Conditions
- Heart Transplant, Acute Graft Rejection, Chronic Graft Rejection
- Trial name
- NCT02597543
- Testing
- Regadenoson, Gadolinium, Cardiac MRI
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Paul Kim
Cardiac Allograft Vasculopathy, Transplanted Heart Complication
Effect of Ivabradine on Exercise Capacity After Heart Transplantation
This study evaluates whether treatment with ivabradine compared to placebo can improve exercise capacity in long-term heart transplant recipients with cardiac allograft vasculopathy and elevated heart rate at rest.
- Trial name
- VANISH-CAV (NCT03405831)
- Testing
- Ivabradine
- Where
- Denmark
- Volunteers
- 35 people
- Sponsor
- Finn Gustafsson
Disorder Related to Cardiac Transplantation
Heart Transplant Registry of Városmajor
The purpose of this registry is to determine the long term outcomes of heart transplantations performed at the Semmelweis University Heart and Vascular Center.
- Trial name
- NCT02347371
- Where
- Hungary
- Volunteers
- 11 people
- Sponsor
- Semmelweis University Heart and Vascular Center
Disorder Related to Cardiac Transplantation
Assessment of Cardiac Allograft Vasculopathy by Optical Coherence Tomography
Cardiac allograft vasculopathy (CAV) is characterized by marked intimal proliferation and concentric vascular thickening and fibrosis. CAV remains the leading cause of late morbidity and mortality in heart transplant recipients.
- Trial name
- EARLY-OCT (NCT02503566)
- Testing
- Optical coherence tomography
- Where
- 2 sites in Czechia
- Volunteers
- 150 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Cardiac Allograft Vasculopathy
Optical Coherence Tomography (OCT) to Evaluate Cardiac Allograft Vasculopathy (CAV) in Patient's Post Heart Transplant
Cardiac allograft vasculopathy (CAV) is a unique form of accelerated plaque formation seen in the coronary arteries of patients who have received heart transplantation.
- Trial name
- OCTCAV (NCT01403142)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Columbia University
Cardiac Allograft Vasculopathy
Early Post Transplant Cardiac Allograft Vasculopathy
Heart transplantation is an effective life-saving treatment for patients with end-stage heart disease. After a transplant, the new heart may develop narrowing in the arteries, causing heart failure, heart attacks and abnormal…
- Trial name
- ECAV (NCT03217786)
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Psychiatric Diagnosis, Cognition Disorders
Mood and Cognitive Outcome After Heart Transplantation (the MOODHEART Study)
The investigators aim at characterizing neuropsychiatric consequences of heart transplantation (HTX) and at assessing the impact of depressive symptoms after HTX on mortality and cardiac allograft vasculopathy (CAV).
- Trial name
- NCT02035865
- Where
- Norway
- Volunteers
- 74 people
- Sponsor
- Oslo University Hospital
Cardiac Allograft Vasculopathy
Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation
The purpose of this study is to determine the benefit of using the FDA-approved insulin-sensitizing agent, Pioglitazone, on human heart transplant recipients.
- Trial name
- NCT01186250
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Stanford University
Cardiac Allograft Vasculopathy
Noninvasive Evaluation of Cardiac Allograft Vasculopathy
Abnormal peripheral endothelial function and alterations in circulating biomarkers that are associated with endothelial activation and inflammation correlate with angiographic evidence of cardiac allograft vasculopathy, defined…
- Trial name
- CAVII (NCT01305382)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Minnesota
Heart Transplantation
Advanced Cardiac Imaging in Cardiac Allograft Vasculopathy
Cardiac allograft vasculopathy (CAV) is a process of both immune and non-immune mediated thickening of the heart arteries of transplanted hearts.
- Trial name
- NCT01927614
- Testing
- Cardiac CT
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Nova Scotia Health Authority
Cardiac Allograft Vasculopathy
Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy
Is real-time myocardial perfusion echocardiography (RTMPE) a feasible and effective non-invasive method to detect significant Coronary Allograft Vasculopathy in pediatric and adult cardiac transplant recipients? Will perfusion…
- Trial name
- NCT02880137
- Testing
- Perflutren Lipid Microsphere, RTMPE
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
Cardiac Allograft Vasculopathy
MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation
Cardiac allograft vasculopathy (CAV) is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction.
- Trial name
- NCT06089486
- Testing
- ICA, PET
- Where
- 5 sites in Canada
- Volunteers
- 576 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Cardiac Allograft Vasculopathy
Assessment of Cardiac Allograft Vasculopathy With Optical Coherence Tomography
Cardiac allograft vasculopathy (CAV) is a progressive disease of the coronary arteries in transplanted hearts which is a significant cause of morbidity and mortality.
- Trial name
- CAV-OCT-IVUS (NCT01527344)
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Mayo Clinic
Cardiac Allograft Vasculopathy
Noninvasive Predictors of Transplant Vasculopathy
Post transplant vasculopathy is a major negative outcome in heart transplantation. Current methods of detection are highly invasive and pose a risk to transplant recipients.
- Trial name
- CAV (NCT01424917)
- Where
- United States
- Sponsor
- University of Minnesota
Heart Transplant Recipients
Autonomic Cardiovascular Control After Heart Transplantation
The purpose of this prospective study is to investigate denervation (ie. surgical cutting of autonomic nerves) and re-innervation (ie. growth of autonomic nerves) in heart transplant recipients. More specifically, we focus on: 1.
- Trial name
- AccHeart (NCT01759966)
- Where
- Norway
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Cardiac Allograft Vasculopathy
Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients
The main goal of this study is to evaluate the effect of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab on cardiac allograft vasculopathy in de novo heart transplant recipients.
- Trial name
- EVOLVD (NCT03734211)
- Testing
- Evolocumab
- Where
- 5 sites in Denmark, Finland and 1 more
- Volunteers
- 130 people
- Sponsor
- Lars Gullestad
Cardiac Allograft Vasculopathy
Potential Role of Donor-derived Cell-Free DNA as a Biomarker in Cardiac Allograft Vasculopathy
Cross-sectional study. We will prospectively obtain ddcf-DNA levels in all patients who undergo routine coronary angiography > 1 year after HT.
- Trial name
- FreeDNA-CAV (NCT04791852)
- Testing
- Donor-derived Cell Free DNA
- Where
- Spain
- Volunteers
- 94 people
- Sponsor
- Puerta de Hierro University Hospital
Pediatric Heart Transplantation, Immunosuppression
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
The TEAMMATE Trial will enroll 210 pediatric heart transplant patients from 25 centers at 6 months post-transplant and follow each patient for 2.5 years.
- Conditions
- Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases, Cardiac Allograft Vasculopathy
- Trial name
- TEAMMATE (NCT03386539)
- Testing
- Everolimus, Tacrolimus, Mycophenolate Mofetil
- Where
- 25 sites in United States
- Volunteers
- 211 people
- Sponsor
- Boston Children's Hospital
Coronary Artery Disease
Real-World Outcomes of Drug-Coated Balloon Angioplasty in Coronary Artery Disease
The Real-World Drug-Coated Balloon Registry (RW-DCB) is an investigator-initiated, multicenter, observational cohort study evaluating the use of drug-coated balloons (DCBs) during percutaneous coronary intervention (PCI) in…
- Trial name
- RW-DCB (NCT07875088)
- Testing
- Coronary Drug-Coated Balloon
- Where
- 5 sites in Mexico, Spain
- Volunteers
- 2,000 people
- Sponsor
- Kristian Rivera
Cardiac Allograft Vasculopathy, Heart Transplant
AERIAL Trial: Antiplatelet Therapy in Heart Transplantation
Cardiac allograft vasculopathy is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction.
- Trial name
- NCT04770012
- Testing
- aspirin, Clopidogrel
- Where
- 3 sites in Canada
- Volunteers
- 135 people
- Sponsor
- Ottawa Heart Institute Research Corporation